Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 11, 2026 - 20:00

Tenaya Therapeutics has reported significant advancements across its pipeline, headlined by promising new data for its lead gene therapy candidates. During the fourth quarter of 2025, the company announced encouraging results for TN-201, targeting MYBPC3-associated hypertrophic cardiomyopathy, and TN-401, aimed at PKP2-associated arrhythmogenic cardiomyopathy. The company is planning further data readouts and pursuing regulatory alignment for both programs throughout 2026.

Beyond its gene therapy portfolio, new research continues to bolster the potential of TN-301, Tenaya’s small molecule HDAC6 inhibitor. Recent preclinical data demonstrated its promise in a model of Duchenne Muscular Dystrophy, adding to its potential application in heart failure. Strategically, Tenaya entered into a multi-target research collaboration with Alnylam Pharmaceuticals, aiming to discover new RNAi therapeutics for cardiac diseases.

Financially, a December financing round provided net proceeds of $55.8 million. Combined with an anticipated upfront payment from the Alnylam collaboration, these funds are expected to significantly extend the company's operational cash runway, supporting its ongoing research and clinical development efforts into the future.